Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus OPTIMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus OPTIMINE.
LEVOCETIRIZINE DIHYDROCHLORIDE vs OPTIMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
OPTIMINE (azathioprine) is a purine analog that inhibits DNA and RNA synthesis by interfering with purine metabolism. It is metabolized to 6-mercaptopurine, which inhibits de novo purine synthesis and suppresses T-lymphocyte proliferation.
5 mg orally once daily in the evening.
1 mg orally twice daily; maximum 4 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life of 12-15 hours in healthy adults, prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Renal: 65-75% as unchanged drug; biliary/fecal: 20-30% as metabolites; minor hepatic metabolism via CYP3A4.
Category A/B
Category C
Antihistamine
Antihistamine